Daily Anesthesiology Research Analysis
Analyzed 31 papers and selected 3 impactful papers.
Summary
Analyzed 31 papers and selected 3 impactful articles.
Selected Articles
1. Target-controlled infusion vs standard dosing of cefoxitin for surgical prophylaxis in colorectal surgery: A randomized clinical trial.
In 2,494 adults undergoing elective colorectal surgery, pharmacokinetic model-driven cefoxitin TCI did not reduce 30-day SSI versus standard intermittent dosing, but it significantly lowered intraoperative antibiotic exposure by roughly 30% for typical cases. Safety, including AKI incidence, was similar between groups.
Impact: This large RCT provides high-level evidence informing perioperative antibiotic stewardship—showing that PK-guided TCI can reduce exposure without compromising SSI prevention.
Clinical Implications: Routine adoption of cefoxitin TCI solely to prevent SSI is not supported; however, TCI may be considered to minimize antibiotic exposure in selected patients (e.g., prolonged procedures, lower body weight) without increasing infection risk.
Key Findings
- No difference in 30-day SSI between TCI and standard dosing (both 5.6%; RR 1.01, 95% CI 0.73–1.39).
- TCI achieved significantly lower intraoperative cumulative cefoxitin dose (median 1.38 g vs 2.00 g; P<0.001), ≈30% reduction for typical cases.
- Pharmacokinetic simulations indicated larger dosing divergence with longer operative time and lower body weight.
- AKI incidence was not significantly different between groups (17.6% vs 15.7%; P=0.223).
Methodological Strengths
- Large, randomized, parallel-arm design with clear primary endpoint (30-day SSI).
- Pharmacokinetic model-driven TCI with quantitative exposure assessment and simulations.
Limitations
- Single-center setting may limit generalizability.
- Blinding and adherence to CONSORT/antibiotic timing details were not specified in the abstract.
Future Directions: Multicenter trials and adaptive PK/PD-guided strategies should test whether individualized TCI can maintain SSI prevention while further minimizing exposure across diverse patient populations and procedure durations.
OBJECTIVES: To compare the incidence of surgical site infection (SSI) between patients receiving cefoxitin via target-controlled infusion (TCI) and those receiving standard dosing during colorectal surgery, and to evaluate differences in intraoperative antibiotic exposure and postoperative safety outcomes. METHODS: In this single-center, parallel-arm randomized clinical trial, 2,494 adults undergoing elective colorectal surgery between April 2022 and July 2025 were assigned to receive cefoxitin via TCI or the standard dosing method. The TCI group received cefoxitin through a pharmacokinetic model-driven infusion pump targeting a plasma concentration of 80 μg/mL until the end of surgery, whereas the standard group received 2 g every 2 hours up to 8 g. The primary endpoint was the incidence of surgical site infection (SSI) within 30 days postoperatively. Secondary endpoints included intraoperative cumulative cefoxitin dose. Acute kidney injury (AKI) was assessed as an additional safety endpoint. RESULTS: No statistically significant difference in SSI incidence was detected between groups (TCI: 69/1,224 (5.6%) vs standard: 69/1,233 (5.6%); P=0.965; RR: 1.01; 95% CI: 0.73-1.39). The intraoperative cumulative cefoxitin dose was lower in the TCI group (median 1.38 g [IQR, 1.15-1.71]) than in the standard group (2.00 g [2.00-4.00]); Mann-Whitney P<0.001. The median difference was -0.62 g (95% CI, -0.65 to -0.59), representing ∼30% reduction for patients with median operative time (93 min) and body weight (62.5 kg). Pharmacokinetic simulations showed the dosing gap between regimens widened with longer operative duration and lower body weight. AKI incidence did not differ significantly between groups (215/1,224, (17.6%) vs 193/1,233, (15.7%); P=0.223; RR: 1.12; 95% CI: 0.94-1.34). CONCLUSION: In this randomized clinical trial, use of target-controlled infusion of cefoxitin was not associated with a reduction in surgical site infection compared with standard dosing, while resulting in lower intraoperative antibiotic exposure. TRIAL REGISTRATION NUMBER: NCT05253339.
2. Erector spinae plane block for postoperative analgesia in vertebral surgery: An updated meta-analysis of randomized controlled trials with trial sequential analysis and meta-regression.
Across 60 RCTs (n=4167), ESP block produced a modest reduction in 24-hour opioid consumption and early postoperative pain after spine surgery, with trial sequential analysis and meta-regression supporting the robustness of results. Notably, high-certainty evidence supports a significant reduction in PONV.
Impact: This comprehensive, methodologically rigorous synthesis offers decision-ready evidence on ESP block for spine surgery, clarifying benefits and certainty, and informing multimodal analgesia protocols.
Clinical Implications: ESP block can be incorporated as part of multimodal analgesia to achieve small but meaningful opioid-sparing and PONV reduction after vertebral surgery, with patient- and procedure-specific tailoring.
Key Findings
- ESP block reduced 24-hour opioid consumption (MD −8.89 mg MME, 95% CI −11.44 to −6.33; p<0.001).
- Early postoperative pain scores were modestly improved at rest and with movement up to 48 hours.
- High-certainty evidence supports a significant reduction in PONV with ESP block.
- Rigorous methodology: PROSPERO registration, RoB 2 risk of bias assessment, GRADE certainty, TSA, and meta-regression.
Methodological Strengths
- Comprehensive meta-analysis of 60 RCTs with prespecified TSA and meta-regression.
- Risk of bias assessed with RoB 2 and certainty rated with GRADE.
Limitations
- Heterogeneity across trials in block technique, timing, local anesthetic type/dose, and surgical procedures.
- Primary opioid-sparing effect graded as low certainty; long-term outcomes were rarely reported.
Future Directions: Standardized, high-quality RCTs comparing ESP to active regional comparators, with harmonized dosing and patient-centered outcomes (function, chronic pain), are needed to refine indications and quantify benefits.
OBJECTIVES: To evaluate the analgesic efficacy of the erector spinae plane (ESP) block in adults undergoing vertebral surgery and to determine whether the available evidence is sufficient to support definitive conclusions. METHODS: We conducted an updated systematic review and meta-analysis of randomized controlled trials (PROSPERO: CRD42025117873). The primary outcome was 24-h postoperative opioid consumption (morphine milligram equivalents [MME]). Secondary outcomes included pain scores at rest and during movement (0-48 h), rescue analgesia requirement, time to first rescue analgesic, time to mobilization, postoperative nausea and vomiting (PONV), hospital length of stay (LOS), quality of recovery, and chronic postsurgical pain. Random-effects models were used; publication bias was assessed with Egger's test when applicable. Risk of bias was assessed using RoB 2 and certainty using GRADE. Prespecified subgroup analyses, sensitivity analysis, meta-regression for the primary outcome, and trial sequential analysis (TSA) were performed. RESULTS: Sixty trials (n = 4167, ESP block 2081, control 2086) were included. The ESP block was associated with a modest reduction in 24-h opioid consumption (MD -8.89 mg MME, 95% CI -11.44 to -6.33; p < 0.001, I CONCLUSIONS: There is low-certainty evidence supporting a modest reduction in 24-h opioid consumption and early postoperative pain with ESP block in patients undergoing vertebral surgery. In contrast, high-certainty evidence supports a significant reduction in the incidence of PONV.
3. VitalDB Arrhythmia Database: An Anesthesiologist-Validated Large-scale Intraoperative Arrhythmia Dataset with Beat and Rhythm Labels.
This publicly available, anesthesiologist-validated intraoperative ECG dataset includes >660,000 labeled beats and 10 rhythm categories from 482 surgical patients, with excellent inter-rater reliability (Cohen’s kappa ~0.93). It fills a critical gap for developing and benchmarking OR-specific arrhythmia detection algorithms and enables multimodal hemodynamic analyses.
Impact: By providing a rigorously annotated, intraoperative-specific ECG corpus, this work enables reproducible AI research tailored to surgical settings, a longstanding unmet need in anesthesiology monitoring.
Clinical Implications: While not a clinical trial, the dataset supports the development of reliable intraoperative arrhythmia detection and decision-support tools that could improve real-time monitoring and response.
Key Findings
- Contains 734,528 seconds of continuous intraoperative ECG from 482 surgical patients with median annotated duration of 20 minutes.
- Over 660,000 labeled heartbeats spanning 4 beat types and 10 rhythm categories.
- Annotations validated by five anesthesiologists; at least two independent reviews per segment and committee consensus when needed.
- Excellent inter-rater reliability (overall Cohen’s kappa 0.930 ± 0.130).
Methodological Strengths
- Expert, multi-reviewer clinical validation with high inter-rater agreement.
- Automated deep learning pre-screening to efficiently curate large-scale data.
Limitations
- Single-center cohort may limit generalizability across institutions and equipment.
- Median annotated duration per case is relatively short, potentially underrepresenting rare arrhythmias.
Future Directions: Expand to multicenter, longer-duration recordings and integrate synchronized hemodynamic/arterial waveforms to enable outcome-linked algorithm validation.
Intraoperative cardiac arrhythmias present distinct characteristics compared to non-surgical environments, yet publicly available electrocardiogram (ECG) databases have primarily focused on ambulatory or intensive care environments. To address this gap, we present the VitalDB Arrhythmia Database, a comprehensive collection of intraoperative ECG recordings with beat and rhythm labels specifically designed for developing and validating arrhythmia detection algorithms in surgical patients. The database comprises 734,528 seconds of continuous ECG data from 482 surgical patients, with a median annotated recording duration of 20 minutes. It contains over 660,000 annotated heartbeats across four beat types and 10 distinct rhythm categories. To efficiently process the extensive source data, we developed a custom deep learning beat classifier that serves as an automated screening tool for arrhythmia candidate segments. All annotations underwent rigorous validation by five anesthesiologists, with each segment independently reviewed by at least two anesthesiologists, and 9.3% required full committee consensus. Inter-rater reliability analysis demonstrated excellent agreement with an overall Cohen's kappa of 0.930 ± 0.130. This publicly accessible resource provides the research community with clinically validated intraoperative arrhythmia data, facilitating the development of robust arrhythmia detection algorithms and enabling multimodal analysis to investigate the hemodynamic impact of intraoperative arrhythmias.